Ultraviolet radiation, vitamin D and risk of prostate cancer and other diseases

Photochemistry and Photobiology

Volumn 81, Issue 6, 2005, Pages 1252-1260

  Moon, Samuel J ^a   Fryer, Anthony A ^a   Strange, Richard C ^a  

^a KEELE UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VITAMIN D;

FEMALE; GENETIC POLYMORPHISM; GENETICS; HUMAN; MALE; PHYSIOLOGY; PROSTATE TUMOR; REVIEW; ULTRAVIOLET RADIATION;

FEMALE; HUMANS; MALE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; ULTRAVIOLET RAYS; VITAMIN D;

EID: 29844458246     PISSN: 00318655     EISSN: None     Source Type: Journal    
DOI: 10.1562/2005-01-20-IR-421     Document Type: Review

References (90)

1. Moon, S. J., A. A. Fryer and R. C. Strange (2005) Ultraviolet radiation: effects on risks of prostate cancer and other internal cancers. Mutat. Res. 571, 207-219.
2. Strange, R. C., P. Hoban and A. Salim (2002) Skin cancer and exposure to sunlight, polycyclic aromatic hydrocarbons, and arsenic. Clin. Occup. Environ. Med. 2, 803-828.
3. Karagas, M. R. and E. R. Greenberg (1995). Unresolved issues in the epidemiology of basal cell and squamous cell skin cancer. In Skin Cancer: Mechanisms and Human Relevance (Edited by H. Mukhtar), pp. 79-86. CRC Press, Boca Raton, FL.
4. Armstrong, B. K. and A. Kricker (2001) The epidemiology of UV induced skin cancer. J. Photochem. Photobiol. B 63, 8-18.
5. Boyle, P., P. Maisonneuve and J.-F. Dore (1995) Epidemiology of malignant melanoma. Br. Med. Bull. 51, 523-547.
6. Fitzpatrick, T. B. (1988) The validity and practicality of sun reaction skin types I through VI. Arch. Dermatol. 124, 869-871.
7. Kricker, A., B. K. Armstrong, D. R. English and P. J. Heenan (1991) Pigmentary and cutaneous risk factors for non-melanocytic skin cancer - a case control study. Int. J. Cancer 48, 650-662.
8. Wharton, B. and N. Bishop (2003) Rickets. Lancet 362, 1389-1400.
9. Isaia, G., R. Giorgino, G. B. Rini, M. Bevilacqua, D. Maugeri and S. Adami (2003) Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors. Osteoporos. Int. 14, 577-582.
10. Plotnikoff, G. A. and J. M. Quigley (2003) Prevalence of severe hypovitaminosis D in patients with persistent non-specific musculoskeletal pain. Mayo Clin. Proc. 78, 1457-1459.
11. Gessner, B. D., J. Plotnik and P. T. Muth (2003) 25-Hydroxyvitamin D levels among healthy children in Alaska. J. Pediatr. 143, 422-423.
12. Stokstad, E. (2003) Nutrition. The vitamin D deficit. Science 302, 1886-1888.
13. Raiten, D. J. and M. F. Picciano (2004) Vitamin D and health in the 21st century: bone and beyond. Executive summary. Am. J. Clin. Nutr. 80 (Suppl.), 1673S-1677S.
14. Holick, M. F. (2003) Evolution and function of vitamin D. Recent Results Cancer Res. 164, 3-28.
15. Holick, M. F. (2004) Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis, Am. J. Clin. Nutr. 79, 362-371.
16. Whitfield, G. K., J. C. Hsieth, P. W. Jurutka, S. H. Selznick, C. A. Haussler, P. N. MacDonald and M. R. Haussler (1995) Genomic actions of 1,25-dihydroxyvitamin D3. J. Nutr. 125, 1690s-1694s.
17. Carlberg, C. (2003) Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. Recent Res. Cancer Res. 164, 29-42.
18. Bohnsack, B. L. and K. K. Hirschi (2004) Nutrient regulation of cell cycle progression. Annu. Rev. Nutr. 24, 433-453.
19. Peng, L., P. J. Malloy and D. Feldman (2004) Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol. Endocrinol. 18, 1109-1119.
20. Maestro, B., N. Davila, M. C. Carranza and C. Calle (2003) Identification of a vitamin D response element in the human insulin receptor gene promoter. J. Steroid Biochem. Mol. Biol. 84, 223-230.
21. DeLuca, H. F. and M. T. Cantorna (2001) Vitamin D: its role and uses in immunology. FASEB J. 15, 2579-2585.
22. Hankey, B. F, E. J. Feuer, L. X. Clegg, R. B. Hayes, J. M. Leger, P. C. Prorok, L. A. Ries, R. M. Merril and R. S. Kaplan (1999) Cancer surveillance series interpreting trends in prostate cancer-part 1: evidence of the effects of screening in recent prostate cancer incidence, mortality and survival rates. J. Natl. Cancer Inst. 91, 1017-1024.
23. Glover, F. E., D. S. Coffey, L. L. Douglas, M. Cadogan, H. Russell, T. Tulloch, T. D. Baker, R. L. Wan and P. C. Walsh (1999) The epidemiology of prostate cancer in Jamaica. J. Urol. 159, 1984-1986.
24. Osegbe, D. N. (1997) Prostate cancer in Nigeria facts and nonfacts. J. Urol. 157, 1340-1343.
25. Landis, S. H., T. Murray, S. Bolden and P. A. Wingo (1998) Cancer statistics, 1998. CA Cancer J. Clin. 48, 3133-3275.
26. Muir, C. S., J. Nectoux and J. Staszewinski (1991) The epidemiology of prostatic cancer, geographical, distribution and time trends. ACTA Oncol. 30, 133-140.
27. Shimizu, H., R. K. Ross, L. Bernstein, R. Yatani, B. E. Henderson and T. M. Mack (1991) Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br. J. Cancer 63, 963-966.
28. Shimizu, H., R. K. Ross, and L. Bernstein (1991) Possible underestimation of the incidence rate of prostate cancer in Japan. Jpn. J. Cancer Res. 82, 483-485.
29. Pienta, K. J. and P. S. Esper (1993) Risk factors for prostate cancer. Ann. Intern. Med. 118, 793-803.
30. Peller, S. (1936) Carcinogenesis as a means of reducing cancer mortality. Lancet 2, 552-556.
31. Garland, F. C., C. F. Garland, E. D. Gorham and J. F. Young (1990) Geographic variation in breast cancer mortality in the United States: a hypothesis involving exposure to healthy radiation. Prev. Med. 19, 614-622.
32. Hanchette, C. L. and G. G. Schwartz (1992) Geographic patterns of prostate cancer mortality: evidence for a protective effect of ultraviolet radiation. Cancer 70, 2861-2869.
33. Luscombe, C. J., A. A. Fryer, M. E. French, S. Liu, M. F. Saxby, P. W. Jones and R. C. Strange (2001) Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostate cancer. Lancet 358, 641-642.
34. Young, J. M., D. J. Muscatello and J. E. Ward (2000) Are men with lower urinary tract symptoms at increased risk of prostate cancer? A systematic review and critique of the available evidence. Brit. J. Urol. Int. 85, 1037-1048.
35. Ramsay, H. M., A. A. Fryer, S. Reece, A. G. Smith and P. N. Harden (2000) Clinical risk factors associated with non-melanoma skin cancer in renal transplant recipients. Am. J. Kidney Dis. 36, 167-176.
36. Bodiwala, D., C. J. Luscombe, S. Liu, M. Saxby, M. French, P. W. Jones, A. A. Fryer and R. C. Strange (2003) Prostate cancer risk and exposure to ultraviolet radiation: further support for the protective effect of sunlight. Cancer Lett. 192, 145-149.
37. John, E. M. D. M. Dreon, J. Koo and G. G. Schwartz (2004) Residential sunlight exposure is associated with a decreased risk of prostate cancer. J. Steroid Biochem. Mol. Biol. 89-90, 549-552.
38. Holick, M. F. (1994) McCollum Award Lecture, 1994: Vitamin D - new horizons for the 21st century. Am. J. Clin. Nutr. 60, 619-630.
39. Holick, M. F. and M. Jenkins (2003) The UV Advantage. ibooks, New York.
40. Blair, A. and J. F. Fraumeni (1978) Geographic patterns of prostate cancer mortality in the United States. J. Natl. Cancer Inst. 61, 1379-1384.
41. Bodiwala, D., C. J. Luscombe, M. E. French, S. Liu, M. F. Saxby, P. W. Jones, S. Ramachandran, A. A. Fryer and R. C. Strange (2003) Susceptibility to prostate cancer: studies on interactions between UVR exposure and skin type. Carcinogenesis 24, 711-717.
42. Rampen, F. H. J., B. A. M. Fleuren, T. M. de Boo and W. A. J. G. Lemmens (1988) Unreliability of self-reported burning tendency and tanning ability. Arch. Dermatol. 124, 885-888.
43. Staples, J. A., A.-L. Ponsonby, L. L.-Y. Lim and A. J. Michael (2003) Ecologic analysis of some immune-related disorders, including type 1 diabetes, in Australia: latitude, regional ultraviolet radiation, and disease prevalence. Environ. Health Perspect. 111, 518-523.
44. van der Mei, I. A. F., A. L. Ponsonby, T. Dwyer, L. Blizzard, R. Simmons, B. V. Taylor, H. Butzkueven and T. Kilpatrick (2003) Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. Brit. Med. J. 327, 316-322.
45. Lawrence, J. S., T. Behrend, P. H. Bennett, J. M. Bremner, T. A. Burch, J. Gofton, W. O'Brien and H. Robinson (1966) Geographical studies of rheumatoid arthritis. Ann. Rheum. Dis. 25, 425-432.
46. 3. Cancer Res. 52, 515-520.
47. Lokeshwar, B. L., G. G. Schwartz, M. G. Selzer, K. L. Burnstein, S.-H. Zhang, N. L. Block and L. Binderup (1999) Inhibition of prostate cancer metastasis in vivo: a comparison of 1,25-Dihydroxyvitamin D (Calcitrol) and EB1089. Cancer Epidemiol. Biomarkers Prev. 8, 241-248.
48. 3: a new class of potent inhibitors of proliferation of prostate, breast and myeloid leukaemic cells. Cancer Res. 59, 4023-4029.
49. Blutt, S. E., T. J. McDonnel, T. C. Polek and N. L. Wiegel (2000) Calciriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 141, 10-17.
50. Schwartz, G. G., M. H. Wang, M. Zang, R. K. Singh and G. P. Siegal (1997) 1α25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol. Biomarkers Prev. 6, 727-732.
51. Majeski, S., M. Skopinska, M. Markzak, A. Szmurlo, W. Bollag and S. Jablonska (1996) Vitamin D is a potent inhibitor of tumour cell-induced angiogenesis. J. Investig. Dermatol. Symp. Proc. 1, 97-101.
52. 3 in intestinal tract, stomach, kidney, skin, pituitary and parathyroid. Science 206, 1188-1190.
53. 3. Cancer Epidemiol. Biomarkers Prev. 7, 391-395.
54. Young, M. V., G. G. Schwartz, L. Wang, D. P. Jamieson, L. W. Whitlatch, J. N. Flanagan, B. L. Lokeshwar, M. F. Holick and T. C. Chen (2004) The prostate 25-hydroxyvitamin D-1-alpha-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis 25, 967-971.
55. 3 production by human keratinocytes. Kinetics and regulation. J. Clin. Invest. 78, 557-566.
56. 3-1 alpha-hydroxylase and vitamin D receptor gene expression in human colonie mucosa is elevated during early carcinogenesis. Steroids 3-5, 287-292.
57. 3-induced growth inhibition. Cancer Res. 61, 2852-2856.
58. Braun, M. M., K. J. Helzlsouer, B. W. Hollis and G. W. Comstock (1995) Prostate cancer and prediagnostic levels of serum vitamin D metabolites. Cancer Causes Control 6, 235-239.
59. Nomura, A. M. Y., G. N. Stemmermann, J. Lee, L. N. Kolonel, T. C. Chen, A. Turner and M. F. Holick (1998) Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 9, 425-432.
60. Corder, E. H., H. A. Guess, B. S. Hulka, G. D. Friedman, M. Sadler, R. T. Volmer, B. Lobaugh, M. K. Drezner, J. H. Vogelman and N. Orentreich (1993) Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol. Biomarkers Prev. 2, 467-472.
61. Ahonen, M. H., L. Tenkanen, L. Teppo, M. Hakama and P. Tuihimaa (2000) Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11, 847-852.
62. Tuohimaa, P., L. Tenkanen, M. Ahonen, S. Lumme, E. Jellum, G. Hallmans, P. Stattin, S. Harvei, T. Hakulinen, T. Luostarinen, J. Dillner, M. Lehtinen and M. Hakama (2004) Both high and low levels of blood vitamin D are associated with higher prostate cancer risk: a longitudinal, nested case control study in the Nordic countries. Int. J. Cancer 108, 104-108.
63. Clark, A. G. (2003) Finding genes underlying risk of complex disease by linkage disequilibrium mapping. Curr. Opin. Genet. Dev. 13, 296-302.
64. Nam, R. K., W. W. Zhang, J. Trachtenberg, M. A. S. Jewitt, M. Emami, D. Vesprini, W. Chu, M. Ho, J. Sweet, A. Evans, A. Toi, M. Pollack and S. A. Narod (2003) Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 12, 1429-1437.
65. Ntais, C., A. Polycarpou and J. P. A. Ioannidis (2003) Vitamin D receptor polymorphism and risk of prostate cancer: a meta-analysis. 12, 1395-1402.
66. Sturm, R. A. (2002) Skin colour and skin cancer- MC1R, the genetic link. Melanoma Res. 12, 405-416.
67. Oetting, W. S. and R. A. King (1999) Molecular basis of albinism: mutations and polymorphisms of pigmentation genes associated with albinism. Hum. Mutat. 13, 99-115.
68. Ichii-Jones, F., J. T. Lear, A. H. M. Heagerty, A. G. Smith, P. E. Hutchinson, J. Osborne, B. Bowers, P. W. Jones, E. Davies, W. E. R. Ollier, W. Thomson, L. Yengi, J. Bath, A. A. Fryer and R. C. Strange (1998) Susceptibility to malignant melanoma: influence of skin type and polymorphism in the melanocyte stimulating hormone receptor gene. J. Invest. Dermatol. 111, 218-221.
69. Box, N. F., J. R. Wyeth, L. E. O'Gorman, N. G. Martin and R. A. Sturm (1987) Characterization of melanocyte stimulating hormone receptor variant alleles in twins with red hair. Hum. Mol. Genet. 6, 1891-1897.
70. Luscombe, C. J., M. E. French, S. Liu, M. F. Saxby, P. W. Jones, A. A. Fryer and R. C. Strange (2001) Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes, Br. J. Cancer 85, 1504-1509.
71. Partridge, J. M., S. J. M. Weatherby, J. A. Woolmore, D. J. Highland, A. A. Fryer, C. L. A. Mann, M. D. Boggild, W. E. R. Ollier, R. C. Strange and C. P. Hawkins (2004) Susceptibility and outcome in MS. Neurology 62, 2323-2325.
72. Uitterlinden, A. G., Y. Fang, J. B. J. van Meurs, H. A. P. Pols and J. P. T. M. van Leeuwen (2004) Genetics and biology of vitamin D receptor polymorphisms. Gene 338, 143-156.
73. Nejentsev, S., L. Godfrey, H. Snook, H. Rance, S. Nutland, N. M. Walker, A. C. Lam, C. Guja, C. Ionescu-Tirgoviste, D. E. Undlien, K. S. Ronningen, E. Tuomilehto-Wolf, J. Tuomilehto, M. J. Newport, D. G. Clayton and J. A. Todd (2004) Comparative high-resolution analysis of linkage disequilibrium and tag single nucleotide polymorphisms between populations in the vitamin D gene. Hum. Mol. Genet. 13, 1633-1639.
74. Morrison, N. A., R. Yeoman, P. J. Kelly and J. A. Eisman (1992) Contribution of trans-acting factor alleles to normal physiological variability: vitamin D receptor polymorphism and circulating osteocalcin. Proc. Natl. Acad. Sci. USA 89, 6665-6669.
75. Morrison, N. A., J. C. Qi, A. Tokita, P. J. Kelly, L. Crofts, T. V. Nguyen, P. N. Sambrook and J. A. Eisman (1994) Prediction of bone density from vitamin D receptor alleles. Nature 367, 284-287.
76. Arai, H., K. Miyamoto, Y. Taketani, H. Yamamoto, Y. Iemori, K. Morita, T. Tonai, T. Nishisho, S. Mori and E. Takeda (1997) A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J. Bone Miner. Res. 12, 915-921.
77. Hamasaki, T., H. Inatomi, T. Katoh, T. Ikuyama, and T. Matsumoto (2001) Clinical and pathological significance of vitamin D receptor gene polymorphism for prostate cancer which is associated with a higher mortality in Japanese. Endocr. J. 48, 543-549.
78. Oakley-Girvan, I., D. Feldman, T. R. Eccleshall, R. P. Gallagher, A. H. Wu, L. N. Kolonel, J. Halpern, R. R. Balise, D. W. West, R. S. Paffenbarger, Jr., and A. S. Whittemore (2004) Risk of early onset prostate cancer in relation to germ line polymorphisms of the vitamin D receptor. Cancer Epidemiol. Biomarkers Prev. 13, 1325-1330.
79. Luscombe, C. J., M. E. French, S. Liu, M. F. Saxby, P. W. Jones, A. A. Fryer and R. C. Strange (2001) Outcome in prostate cancer: associations with skin type and polymorphism in pigmentation related genes. Carcinogenesis 22, 1343-1347.
80. Arai, H., K. Miyamoto, M. Yoshida, H. Yamamoto, Y. Taketani, K. Morita, M. Kubota, S. Yoshida, M. Ikeda, F. Watabe, Y. Kanemasa and E. Takeda (2001) The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. J. Bone Miner. Res. 16, 1256-1264.
81. Halsall, J. A., J. E. Osbourne, L. Potter, J. H. Pringle and P. E. Hutchinson (2004) A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibility and prognosis in malignant melanoma. Br. J. Cancer 91, 765-770.
82. Ingles, S. A., R. K. Ross, M. C. Yu, R. A. Irvine, G. La Pera, R. W. Haile and G. A. Coetzee (1997) Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J. Natl. Cancer Inst. 89, 166-170.
83. Bodiwala, D., C. J. Luscombe, M. E. French, S. Liu, M. F. Saxby, P. W. Jones, A. A. Fryer and R. C. Strange (2004) Polymorphisms in the vitamin D receptor gene, ultraviolet radiation and susceptibility to prostate cancer. Environ. Mol. Mutagen. 43, 121-127.
84. Guy, M., L. C. Lowe, D. Bretherton-Watt, J. L. Mansi and K. W. Colston (2003) Approaches to evaluating the association of vitamin D receptor polymorphisms with breast cancer risk. Recent Results Cancer Res. 164, 43-54.
85. Ingles, S. A., D. G. Garcia, W. Wang, A. Nieters, B. E. Henderson, L. N. Kolonel, R. W. Haile and G. A. Coetzee (2000) Vitamin D receptor genotype and breast cancer in Latinas. Cancer Causes Control 11, 25-30.
86. Nejentsev, S., J. D. Cooper, L. Godfrey, J. M. M. Howson, H. Rance, S. Nutland, N. M. Walker, C. Guja, C. Ionescu-Tirgoviste, D. A. Savage, D. E. Undlien, K. S. Rønningen, E. Tuomilehto-Wolf, J. Tuomilehto, K. M. Gillespie, S. M. Ring, D. P. Strachan, B. Widmer, D. Dunger and J. A. Todd (2004) Analysis of the vitamin D receptor gene sequence variants in type 1 diabetes. Diabetes 53, 2709-2712.
87. Trump, D. L., P. A. Hershberger, R. J. Bernardi, S. Ahmed, J. Muindi, M. Fakih, W. D. Yu and C. S. Johnson (2004) Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J. Steroid Biochem. Mol. Biol. 89-90, 519-526.
88. Beer, T. M., M. Garzotto, W. D. Henner, K. M. Eilers and E. M. Wersinger (2004) Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br. J. Cancer 91, 1425-1427.
89. Rostand, S. G. (1998) Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 30, 150-156.
90. Egan, K. M., J. A. Sosman and W. J. Blot (2005) Sunlight and reduced risk of cancer: is the real story vitamin D? J. Natl. Cancer Inst. 97, 161-163.